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Uncovering the Shroud




Coronary Intervention*Matthew T. Roe, MD, MHS,
Matthew W. Sherwood, MD
Durham, North Carolina
The contemporary management of patients with acute
ST-segment elevation myocardial infarction (STEMI) in the
United States has focused upon increasing the timely access to
primary percutaneous coronary intervention (PCI) through
nationwide quality improvement efforts and the establishment
of regional STEMI systems of care across the country (1,2).
Nonetheless, because only one-third of the approximately
5,000 acute care hospitals in the United States have PCISee page 604capabilities, primary PCI is not rapidly available to all patients
with STEMI. As an alternative to primary PCI, initial
reperfusion with ﬁbrinolytic agents is endorsed as a Class IA
recommendation by the revised STEMI guidelines when it is
estimated that the transfer time to a PCI-capable hospital
cannot be expedited to achieve the goal of ﬁrst medical
contact to device activation of <120 min (3–5). Although the
nationwide use of primary PCI versus ﬁbrinolytic agents as
the initial reperfusion strategy in contemporary practice is
unknown, data from a comprehensive statewide STEMI
program conducted from 2008 to 2009 demonstrated that
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initially, and 5% did not receive reperfusion therapy (6).
Recommendations for the use of adjunctive oral anti-
platelet therapies (in addition to aspirin) were clariﬁed in the
recently updated STEMI guidelines (5). These guidelines
endorse a Class IB recommendation for clopidogrel, prasu-
grel, or ticagrelor for use during primary PCI, a Class IA
recommendation for clopidogrel to be given together with
ﬁbrinolytic therapy, a Class IC recommendation for clopi-
dogrel when PCI is performed after ﬁbrinolytic therapy, and
a Class IIA-B recommendation for prasugrel when PCI is
performed after ﬁbrinolytic therapy (with speciﬁcations on
the timing and type of ﬁbrinolytic used relative to the timing
of the PCI procedure) (5). Although the more potent, third-
generation P2Y12 antagonists, prasugrel and ticagrelor, have
both been shown to be superior to clopidogrel, these
agents appear to have preferential beneﬁt when used
during primary PCI for STEMI (7,8). However, the rela-
tive beneﬁts of a third-generation P2Y12 antagonist com-
pared with clopidogrel during secondary PCI for STEMI
(performed in the non-emergent setting after ﬁbrinolytic
agents are administered or more than 12 h after symptom
onset for patients who present late into the course of their
infarct) are uncertain as reﬂected in the cautious guidelines
recommendation for prasugrel for this indication (5).
In this issue of JACC: Cardiovascular Interventions, Udell
et al. (9) present the data from the TRITON–TIMI 38
trial (Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis In Myocardial Infarction 38) for the relative
beneﬁts of prasugrel versus clopidogrel during PCI for the
subgroup of STEMI patients stratiﬁed by primary versus
secondary PCI (68% vs. 32% of the STEMI patients, res-
pectively). Patients in this trial did not receive a P2Y12 an-
tagonist as part of routine care before randomization, and the
median time from symptom onset to randomization was ap-
proximately 4 h versus 48 h for the 2 groups, respectively.
Although there was no signiﬁcant interaction by PCI type for
the treatment effect of prasugrel versus clopidogrel in reducing
the incidence of the primary endpoint of cardiovascular death,
MI, or stroke through 15 months, patients undergoing sec-
ondary PCI appeared to derive enhanced relative beneﬁt with
an apparent augmentation of the event rate in the clopidogrel
treatment arm in this group. When events through 30 days
were analyzed, a signiﬁcant treatment interaction was observed
for all MI events (p ¼ 0.01) that was driven by a differential
reduction of periprocedural MI events with prasugrel in the
secondary versus primary PCI groups, whereas there was a
consistent treatment beneﬁt with prasugrel for nonpro-
cedural MI events in both groups. Formal interaction testing
conﬁrmed these ﬁndings, whereas landmark analyses start-
ing 3 days after the index PCI procedure demonstrated
consistent relative reductions in the primary endpoint with
prasugrel for both the primary and secondary PCI groups.
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614Collectively, these results provide important clariﬁcations
for the relative beneﬁts of prasugrel observed in the STEMI
population, but also uncover a number of interesting ﬁndings
from the trial. First, although 29% of the secondary PCI
patients received ﬁbrinolytic therapy at a median time of 2.2
days before randomization, this group ostensibly should not
have included patients with failed ﬁbrinolytic therapy and
who underwent rescue PCI because patients treated with
ﬁbrinolytic agents in the prior 24 to 48 h (depending upon
ﬁbrin speciﬁcity of the agent used) were excluded from the
TRITON trial. However, data regarding initial reperfusion
success following ﬁbrinolytic agents and the occurrence and
timing of recurrent ischemic events before randomization and
PCI for this group were not collected. Second, the reasons for
nonuse of reperfusion therapy for the 71% of secondary PCI
patients not treated with ﬁbrinolytic therapy, such as delayed
presentation after symptom onset or contraindications to
ﬁbrinolytic agents were also not collected, so the secondary
PCI patients are likely a heterogeneous group who may not
relate to the typical STEMI patients treated in U.S. practice.
Third, the divergent bleeding results (signiﬁcant treatment
interaction with a higher risk of non-coronary artery bypass
graft Thrombolysis In Myocardial Infarction major bleeding
with prasugrel in the primary PCI group versus a lower risk
with prasugrel in the secondary PCI group) are perplexing
and do not appear to be explained by differences in key
bleeding risk factors (older age, low body weight, prior stroke/
transient ischemic attack) between the groups, yet these
ﬁndings are not emphasized in the paper. Finally, this anal-
ysis carefully delineates a major impediment for the conduct
and interpretation of a trial for a novel antithrombotic agent
administered for STEMI patients undergoing PCI: that is,
confounding by the ascertainment of periprocedural MI
events in the primary versus secondary PCI setting. Except
for obvious angiographic complications detected through core
laboratory review or veriﬁcation of ST-segment re-elevation
after initial ST-segment resolution, the adjudication of peri-
procedural MI events for STEMI patients undergoing pri-
mary PCI by evaluation of cardiac marker trend patterns is
very difﬁcult, given the expected marker elevations related to
the index STEMI events. For patients undergoing secondary
PCI, initial marker elevations likely down trended by the time
PCI was performed, so the detection of periprocedural MI
events was inadvertently facilitated by the inherent delays
to the PCI procedure in this group.
Although the results in the secondary PCI group from the
TRITON trial are hard to extrapolate to contemporary U.S.
practice, these ﬁndings should inform practice guideline
recommendations and the conduct of future trials for
STEMI patients undergoing PCI. The current Class IIA-B
recommendation for the use of prasugrel for STEMI
patients undergoing nonrescue PCI after ﬁbrinolytic
therapy (after the speciﬁed time delays to allow for resolution
of the lytic effect to minimize bleeding risk) should bereconsidered for upgrade in light of these results. Addi-
tionally, given the speciﬁcations of the most recent revisions
to the Universal MI Deﬁnition for the ascertainment of
periprocedural MI events, the MI adjudication plan for a
new STEMI PCI trial should include angiographic core
laboratory review, detailed data collection regarding symp-
toms and electrocardiographic changes during the proce-
dure, and careful documentation of the speciﬁcations of the
local cardiac marker assays utilized (if cardiac marker core
laboratory specimens are not collected) (10,11). Finally, data
are needed from U.S. practice on how STEMI patients who
do not undergo primary PCI are managed in order to better
inform treatment decisions and risk prognostication for
this important and sizable group of patients.
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